Dopexamine Drug Uses, Dosage, Side Effects & Mechanism | DrugsAtlas

Authoritative Clinical Reference

DRUG NAME: Dopexamine

Therapeutic Class: Inotropic Agent

Subclass: Dopaminergic/β2-Adrenergic Agonist

Speciality: Emergency Medicine

Schedule (India): Schedule H

Route(s): Intravenous (infusion only)

Formulations Available in India:
• Injection: 400 mg/5 mL concentrate for infusion (requires dilution in normal saline or 5% dextrose before administration)

Note: Limited availability in India; predominantly used in tertiary care ICU settings

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Acute Low Cardiac Output States
(Post-cardiac surgery, acute decompensated heart failure with preserved blood pressure)

Parameter	Recommendation
Starting dose	0.5 µg/kg/min via continuous IV infusion
Titration	Increase by 0.5 µg/kg/min every 15–30 minutes based on haemodynamic response
Usual maintenance dose	1–2 µg/kg/min
Maximum dose	4 µg/kg/min (up to 6 µg/kg/min in select cases under intensive monitoring)

Clinical Notes:

Tachycardia is the primary dose-limiting adverse effect
Not a vasopressor — do not use when blood pressure is critically low
Requires central venous access for administration
Continuous ECG and invasive arterial BP monitoring mandatory

2. Adjunctive Support for Splanchnic and Renal Perfusion in Shock
(When blood pressure maintained but organ perfusion compromised)

Parameter	Recommendation
Starting dose	0.5–1 µg/kg/min via continuous IV infusion
Titration	Adjust based on urine output, lactate clearance, and clinical response
Usual maintenance dose	1–2 µg/kg/min
Maximum dose	4 µg/kg/min

Clinical Notes:

Not first-line vasopressor or inotrope
Reserved for select patients with adequate MAP but poor organ perfusion
Ensure adequate volume resuscitation prior to initiation
Limited evidence for mortality benefit

Secondary Indications – Adults (Off-label)

Indication	Dose	Duration	Notes
Septic shock with maintained BP but poor organ perfusion — OFF-LABEL	1–2 µg/kg/min as adjunct to norepinephrine	Usually <48 hours	Specialist only; Indian ICU practice; limited RCT evidence
Acute mesenteric ischaemia (adjunct) — OFF-LABEL	0.5–1 µg/kg/min	Short-term (24–48 hours)	Specialist only; case series; rarely used

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

Not applicable. Dopexamine is not approved for routine paediatric use in India.

Secondary Indications – Paediatrics (Off-label)

Weight Category	Starting Dose	Maximum Dose	Setting
<10 kg	0.25 µg/kg/min	2 µg/kg/min	Paediatric cardiac ICU only
10–30 kg	0.5 µg/kg/min	2.5 µg/kg/min	Paediatric cardiac ICU only
>30 kg	0.5 µg/kg/min	4 µg/kg/min	As per adult protocol

All paediatric use is OFF-LABEL

Safety Monitoring:

Continuous ECG and arterial BP monitoring mandatory
Hourly urine output assessment
Monitor for tachyarrhythmias

Minimum Age: NOT RECOMMENDED in neonates or infants except under paediatric cardiac intensivist supervision

Evidence: Limited to case series and extrapolation from adult data; no Indian paediatric guidelines available

RENAL ADJUSTMENT

No specific dose adjustment required.

Parameter	Recommendation
Mild to moderate impairment	Standard dosing with close monitoring
Severe impairment	No accumulation expected due to rapid hepatic metabolism; titrate based on clinical response
Haemodialysis	No supplemental dosing required; haemodynamic monitoring essential

Note: Monitor urine output and serum creatinine as markers of organ perfusion response.

HEPATIC ADJUSTMENT

Hepatic Function	Recommendation
Mild impairment (Child-Pugh A)	Standard dosing; routine monitoring
Moderate impairment (Child-Pugh B)	Start at lower dose (0.5 µg/kg/min); slower titration
Severe impairment (Child-Pugh C)	Use with extreme caution; specialist supervision; consider alternative inotropes

CONTRAINDICATIONS

• Known hypersensitivity to dopexamine or any formulation component
• Severe hypotension (systolic BP <70 mmHg) unresponsive to volume resuscitation
• Uncontrolled tachyarrhythmias (atrial fibrillation with ventricular rate >130 bpm, ventricular tachycardia)
• Pheochromocytoma
• Hypertrophic obstructive cardiomyopathy
• Concurrent use with MAO inhibitors or within 14 days of MAOI discontinuation

CAUTIONS

• Ischaemic heart disease — may precipitate angina or myocardial ischaemia
• History of atrial or ventricular arrhythmias
• Severe hepatic impairment
• Hypovolaemia — correct volume deficit before initiation
• Concurrent sympathomimetic therapy — additive cardiovascular effects
• Hypokalaemia or hypomagnesaemia — increases arrhythmia risk
• Abrupt discontinuation — taper gradually to avoid rebound hypotension

PREGNANCY

Parameter	Recommendation
Overall safety	Not established; limited human data
Risk category	Use only if potential benefit justifies fetal risk
Preferred alternatives	Dobutamine, dopamine (more established safety profile in obstetric critical care)
When to consider	Life-threatening maternal cardiac decompensation unresponsive to first-line agents
Monitoring	Continuous maternal BP, heart rate; fetal heart rate monitoring if viable gestation

LACTATION

Parameter	Information
Compatibility	Unknown; use with caution
Expected milk levels	Likely low due to short half-life and rapid metabolism
Preferred alternatives	Dobutamine if inotropic support needed in lactating mother
Infant monitoring	Tachycardia, irritability, feeding difficulties
Recommendation	Avoid breastfeeding during active infusion; may resume after drug clearance (half-life ~7 minutes)

ELDERLY

Parameter	Recommendation
Starting dose	0.5 µg/kg/min (lower end of range)
Titration	Slower — increase at 30-minute intervals
Special risks	Higher susceptibility to tachyarrhythmias, myocardial ischaemia, hypotension
Monitoring	Continuous ECG; frequent renal function assessment; electrolyte monitoring

MAJOR DRUG INTERACTIONS

Interacting Drug	Mechanism/Effect	Recommendation
MAO inhibitors	Risk of hypertensive crisis due to potentiated catecholamine effects	Contraindicated — avoid concurrent use or within 14 days
Halogenated anaesthetics (halothane, isoflurane)	Sensitisation of myocardium to catecholamines; increased arrhythmia risk	Avoid combination; inform anaesthetist
Non-selective beta-blockers	Antagonism of β2-mediated inotropic and vasodilatory effects	Avoid if possible; reduced efficacy expected
Other sympathomimetics (adrenaline, noradrenaline, dobutamine)	Additive cardiovascular stimulation	Use with caution; increased tachycardia and arrhythmia risk

MODERATE DRUG INTERACTIONS

Interacting Drug	Effect	Recommendation
Loop diuretics	Volume depletion potentiates hypotensive risk	Ensure euvolaemia before initiation; monitor BP
Digoxin	Additive pro-arrhythmic potential	ECG monitoring; caution in digitalis toxicity
Nitrates (GTN, isosorbide)	Combined hypotensive effect	Monitor perfusion pressure closely
Potassium-depleting agents	Hypokalaemia increases arrhythmia susceptibility	Monitor electrolytes; correct deficits
Insulin	β2-agonist effect may cause hyperglycaemia	Monitor blood glucose

COMMON ADVERSE EFFECTS

• Tachycardia (dose-limiting; most frequent)
• Palpitations
• Nausea and vomiting
• Headache
• Facial flushing
• Tremor
• Restlessness
• Chest discomfort

SERIOUS ADVERSE EFFECTS

Adverse Effect	Clinical Action
Ventricular arrhythmias (VT, VF)	Immediate discontinuation; ACLS protocol
Myocardial ischaemia / Angina	Reduce dose or discontinue; evaluate for ACS
Severe hypotension	Discontinue; volume resuscitation; consider vasopressor
Metabolic acidosis	Check lactate; reassess perfusion; may indicate inadequate response
Supraventricular tachyarrhythmias	Rate control; dose reduction or discontinuation

MONITORING REQUIREMENTS

Baseline:
• 12-lead ECG
• Invasive arterial blood pressure (preferred) or continuous non-invasive BP
• Serum electrolytes (K⁺, Mg²⁺)
• Renal function (serum creatinine, urine output)
• Lactate level
• Central venous pressure / fluid status assessment

During infusion:
• Continuous ECG monitoring
• Arterial BP — continuous
• Urine output — hourly
• Heart rate — continuous (tachycardia is dose-limiting)
• Central venous pressure (if available)

After dose change:
• Reassess haemodynamics within 15–30 minutes
• Repeat ECG if arrhythmia suspected

If infusion >24 hours:
• Serial electrolytes (especially K⁺)
• Lactate trend
• Acid-base status
• Renal function

BRANDS AVAILABLE IN INDIA

Brand Name	Manufacturer	Formulation
Dopacard	Neon Laboratories	400 mg/5 mL concentrate

Note: Limited market availability; primarily stocked in tertiary care ICUs

PRICE RANGE (INR)

Formulation	Approximate Price
400 mg/5 mL vial	₹3,000–4,000 per vial

• NLEM status: Not listed
• NPPA price control: Not applicable
• Availability: ICU procurement channels; limited in government hospitals; costly relative to dobutamine/dopamine

CLINICAL PEARLS

• Dopexamine is an inodilator, not a vasopressor — avoid use when blood pressure is critically low; it will worsen hypotension

• Tachycardia is the most common dose-limiting effect — if heart rate exceeds 120–130 bpm, reduce infusion rate or discontinue

• Ensure adequate preload before initiating therapy — hypovolaemia will exacerbate hypotension

• Consider dobutamine as first-line alternative — it is more widely available, less expensive, and has more established efficacy data in Indian critical care practice

• Short-term use only — typically limited to 24–72 hours; not indicated for chronic heart failure management

• The theoretical benefit for splanchnic/renal perfusion via dopaminergic receptor activation has limited clinical outcome data — do not rely on this as primary therapeutic goal

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.